Form 4: Intra-Cellular Therapies Executive VP Sells Shares to Cover Tax Obligations

Mark Neumann, EVP and Chief Commercial Officer of Intra-Cellular Therapies, sold shares of ITCI common stock on February 26, 2024, to cover tax liabilities arising from vesting restricted stock units, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Mark Neumann, the EVP, Chief Commercial Officer of Intra-Cellular Therapies, Inc. (ITCI), reported changes in beneficial ownership of the company's stock.
• On February 23, 2024, Neumann converted 7,907 restricted stock units into common stock.
• On February 26, 2024, Neumann sold a total of 7,907 shares of common stock in multiple transactions at weighted average prices ranging from $68.03 to $71.18 per share.
• These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2023.
• The majority of the proceeds from the sales will be used to cover Neumann's tax liability from the vesting of restricted stock units.
• Following these transactions, Neumann directly owns 29,700 shares of Intra-Cellular Therapies, Inc. common stock.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting transactions. The stock sales are part of a pre-arranged plan, mitigating negative sentiment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which is a common practice for executives to manage their stock holdings and avoid accusations of insider trading.
• The disclosure is transparent and provides detailed information about the transactions, including the dates, prices, and number of shares sold.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. They can be driven by various factors, including personal financial planning, tax obligations, and diversification strategies. The use of Rule 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially causing a slight decrease in the stock price due to increased selling pressure.

Key Dates